Key Findings from Treatment Algorithms: Type 2 Diabetes

Decision Resources, Inc, December 2011, Pages: 41

For more than a decade, U.S. physicians relied heavily upon metformin and the sulfonylureas for the treatment of type 2 diabetes prior to third-line initiation of insulin. However, in recent years, several new drug classes have emerged to challenge these generic agents, and these novel drug classes now contribute significantly to the overall type 2 diabetes market, which topped $20 billion in 2009.

Branded agents vying for space in second-line treatment include the DPP-IV inhibitors Januvia (Merck’s sitagliptin) and Onglyza (Bristol-Myers Squibb/AstraZeneca’s saxagliptin), the PPAR-gamma agonist Actos (Takeda’s pioglitazone), the GLP-1 analogues Byetta (Amylin/Eli Lilly’s exenatide) and Victoza (Novo Nordisk’s liraglutide), and the insulin analogues Lantus (Sanofi-Aventis’s insulin glargine) and Levemir (Novo Nordisk’s insulin detemir).

This report provides an insight into which of these agents is winning the greatest patient share in newly diagnosed patients as well as recently treated patients, and how newer agents such as Onglyza and Victoza are faring against their more-established competitors. Using patient-level claims data, this report determines the share of each currently marketed drug by line of therapy, evaluates therapy flow, and analyzes why key drugs are chosen over others.

1. Background
a) Publication Update
b) Report Contents and Features
c) Current Practice Guidelines
d) Key U.S. Market Events Influencing Treatment Selection

2. Key Findings for Newly Diagnosed Patients
a) Executive Summary
b) Graphical Views

3. Key Findings for Recently Treated Patients
a) Executive Summary
b) Graphical Views

4. Key Findings by Product
a) Januvia
b) Onglyza
c) Byetta
d) Victoza
e) Actos
f) Lantus
g) Levemir

5. Appendix: Methodology

Customers who bought this item also bought

• Thought Leader Insight & Analysis Report - Diabetes/Obesity Q4 2010
• The Diabetes Market Outlook: Market Analysis of Future Growth and Leading Players by Sector
• Type 2 Diabetes (Event Driven)
• Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.
• Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers
• The Global Diabetes Market: Therapeutics, Diagnostics and Complications
• Pipeline Insight: Insulin Antidiabetics - Novel analogs show promise as alternative delivery methods prove less attractive.
• Indian Diabetes Market Report & Outlook For 2010-2015
• Indian Diabetes Market Outlook 2010-2015
• R&D Trends: Insulin Antidiabetics - The Future is Analogs